Genovis AB (publ.) Resultados de beneficios anteriores

Pasado controles de criterios 6/6

Genovis AB (publ.) ha aumentado sus beneficios a una tasa media anual de 54.5%, mientras que los beneficios de la industria de Life Sciences han experimentado un crecimiento de 30.7% anual. Los ingresos han ido creciendo a una tasa media de 28.2% al año. La rentabilidad financiera de Genovis AB (publ.) es de 32.2%, y sus márgenes netos son de 38.7%.

Información clave

54.5%

Tasa de crecimiento de los beneficios

54.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Life Sciences	31.8%
Tasa de crecimiento de los ingresos	28.2%
Rentabilidad financiera	32.2%
Margen neto	38.7%
Próxima actualización de resultados	15 May 2024

Actualizaciones de resultados anteriores recientes

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Feb 22

Recent updates

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 26

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Mar 18

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

Feb 28

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Feb 22

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Feb 20

If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

Jul 08

Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

Jun 01

Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%

May 10

One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically

Feb 10

Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?

Aug 09

What Is Genovis AB (publ.)'s (STO:GENO) Share Price Doing?

Mar 27

How Does Genovis AB (publ.)'s (STO:GENO) CEO Pay Compare With Company Performance?

Dec 30

Is Now An Opportune Moment To Examine Genovis AB (publ.) (STO:GENO)?

Nov 23

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Genovis AB (publ.). Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OM:GENO Ingresos, gastos y beneficios (SEK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	159	62	79
30 Sep 23	158	54	78
30 Jun 23	151	57	76
31 Mar 23	142	42	73
31 Dec 22	104	11	68
30 Sep 22	119	41	64
30 Jun 22	112	36	60
31 Mar 22	111	36	57
31 Dec 21	94	25	53
30 Sep 21	71	11	52
30 Jun 21	69	12	51
31 Mar 21	65	9	50
31 Dec 20	61	6	47
30 Sep 20	54	-3	46
30 Jun 20	64	3	43
31 Mar 20	60	6	41
31 Dec 19	61	10	39
30 Sep 19	58	12	36
30 Jun 19	43	5	33
31 Mar 19	40	1	32
31 Dec 18	35	-2	30
30 Sep 18	31	-4	29
30 Jun 18	27	-6	28
31 Mar 18	24	-7	28
31 Dec 17	23	-8	28
30 Sep 17	21	-9	28
30 Jun 17	21	-9	27
31 Mar 17	20	-14	31
31 Dec 16	19	-15	37
30 Sep 16	17	-16	39
30 Jun 16	16	-21	42
31 Mar 16	14	-18	40
31 Dec 15	14	-20	35
30 Sep 15	13	-25	41
30 Jun 15	11	-24	36
31 Mar 15	10	-23	30
31 Dec 14	10	-22	26
30 Sep 14	8	-20	24
30 Jun 14	10	-17	24
31 Mar 14	11	-16	23
31 Dec 13	10	-16	23
30 Sep 13	10	-19	21
30 Jun 13	9	-19	21

Ingresos de calidad: GENO tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (38.9%) de GENO son superiores a los del año pasado (10.8%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: GENO ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 54.5% al año.

Acelerando crecimiento: El crecimiento de los beneficios de GENO en el último año (449.5%) supera su media de 5 años (54.5% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de GENO en el último año (449.5%) superó al de la industria Life Sciences 46.4%.

Rentabilidad financiera

Alta ROE: La rentabilidad financiera (32.2%) de GENO se considera alta.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Genovis AB (publ.) Resultados de beneficios anteriores

Pasado controles de criterios 6/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS and revenues miss analyst expectations

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Genovis AB (publ.) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: EPS misses analyst expectations

Genovis AB (publ.) to Report First Half, 2024 Results on Aug 20, 2024

Recent updates

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 19%

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 16% to kr61.50

Group Chief Financial Officer recently bought kr130k worth of stock

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Price target decreased by 7.5% to kr68.00

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Genovis AB (publ.) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 35%

Genovis AB (publ.), Annual General Meeting, May 15, 2024

New major risk - Revenue and earnings growth

Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be

Price target decreased by 8.5% to kr73.50

Consensus revenue estimates fall by 13%

New major risk - Earnings quality

Third quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Genovis AB (publ.) to Report First Half, 2024 Results on Aug 20, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 15%

Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors

Genovis AB (publ.) to Report Q1, 2024 Results on May 15, 2024

Consensus EPS estimates increase by 22%

Director recently sold kr27m worth of stock

New major risk - Earnings quality

Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?

Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets

Consensus EPS estimates increase by 21%

What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Chairman of the Board recently bought kr308k worth of stock

Independent Chairman of the Board recently bought kr308k worth of stock

Vice President of Sales & Marketing recently bought kr89k worth of stock

President & CEO recently bought kr118k worth of stock

Consensus EPS estimates increase by 11%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 8.6% to kr76.00

Genovis AB (publ.) to Report Fiscal Year 2023 Results on Feb 15, 2024

Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?

Price target decreased to kr60.00

Third quarter 2022 earnings released: EPS: kr0.087 (vs kr0.013 in 3Q 2021)

Consensus forecasts updated

Genovis AB (publ.) to Report Nine Months, 2023 Results on Nov 15, 2023

Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?

Genovis AB (publ.) to Report Q1, 2023 Results on May 16, 2023

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

Price target decreased to kr80.00

Genovis AB (Publ.) Announces Board Changes

Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%

Consensus forecasts updated

Group Chief Financial Officer recently bought kr96k worth of stock

First quarter 2022 earnings released: EPS: kr0.19 (vs kr0.011 in 1Q 2021)

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Genovis AB (publ.), Annual General Meeting, May 12, 2022

Insider recently bought kr52k worth of stock

Insider recently bought kr52k worth of stock

General Counsel recently bought kr320k worth of stock

Consensus revenue estimates fall by 20%

One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: EPS kr0.013 (vs kr0.02 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.016 (vs kr0.023 loss in 2Q 2020)

Desglose de ingresos y gastos
Beta